HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2007.126003v1 93/2/182    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stowe, J. Articles by Miller, E. Search for Related Content PubMed PubMed Citation Articles by Stowe, J. Articles by Miller, E.

Idiopathic thrombocytopenic purpura and the second dose of MMR

¹ Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
² Statistics, Modelling and Bioinformatics Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK

Correspondence to:
Professor Elizabeth Miller, Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK; liz.miller@hpa.org.uk

The first 150 words of the full text of this article appear below.

An increase in idiopathic thrombocytopenic purpura (ITP) cases in the 6 weeks following the first dose of the measles, mumps and rubella (MMR) vaccine has been established, with absolute risks estimated as 1 in 22 300¹ and 1 in 21 000 vaccine doses,² with two in every three cases attributable to the vaccine. However, the risk after a second dose of MMR vaccine has not been investigated.

Hospital admissions for children aged from 3 to <6 years with a discharge diagnosis of ITP (ICD-code D693 in any diagnosis field) were identified from computerised hospital episode data from North, East and South London, Essex, East Anglia, Sussex and Kent for the period from 1 April 1997 to 31 December 2005. These admissions were then linked to second MMR dose records held on population-based child-health database systems. Only successfully linked admissions were used for the analysis.

A re-admission for ITP within 10 days . . . [Full text of this article]